Although GM-CSF has not been shown to be universally successful in treatment of PAP, its benign side effect profile makes it a useful first line treatment in patients with idiopathic PAP, especially in severe cases where a combined treatment modality can provide an equally efficacious outcome without the risks inherent in WLL [10–12]. This evidence concerns the gene CSF2 and pulmonary alveolar proteinosis.